Jun. 30, 2015News & Opinions
Amine Tahiri has joined the Development Services Sales team of Recipharm as sales director for France with effect from July 1, 2015. Tahiri has more than 16 years of experience in the pharmaceutical industry.
Jun. 08, 2015News & Opinions
In a new international clinical trial, two cancer drugs developed by US drugmaker Bristol-Myers Squibb are reported to have shrunk tumors in nearly 60% of people with advanced melanoma.
Oct. 31, 2014News & Opinions
US drugmaker Bristol-Myers Squibb and Swiss fine and specialty chemicals specialist Lonza have announced a multi-year expansion of their existing biologics manufacturing agreement.
Jun. 11, 2014News & Opinions
Effective August 1, 2014, Dieter Weinand will become president of Bayer HealthCare Pharmaceuticals and at the same time join the Executive Committee of Bayer HealthCare. He replaces Andreas Fibig, who will leave Bayer on September 1, 2014, ...
Jun. 02, 2014News & Opinions
Danish drugmaker Novo Nordisk, the world's biggest insulin producer, has decided to launch its diabetes drug Tresiba in Germany after seeing signs of a more favorable pricing situation there.
Apr. 08, 2014News & Opinions
DKSH Business Unit Healthcare has extended the relationship started in 2010 with Bristol-Myers Squibb, covering six markets in Asia (Hong Kong, Malaysia, Singapore, Taiwan, Thailand and Vietnam).
Dec. 20, 2013News & Opinions
The Supervisory Board of Bayer AG appointed Kemal Malik (51) to the Board of Management of Bayer AG effective February 1, 2014. Malik has been a member of the Bayer HealthCare Executive Committee, Head of Global Development and Chief ...
Oct. 07, 2013News & Opinions
German healthcare company Merck expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin.
Jul. 11, 2013News & Opinions
Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss company as it struggles to diversify outside its core cancer drug portfolio.
Jun. 19, 2013News & Opinions
Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
The latest information directly via newsletter.